Novacyt (ALNOV) H1 2026 TU earnings summary

Executive summary

• Delivered strong H1 2026 performance with 18% year-over-year revenue growth to approximately £11.6 million, driven by organic momentum and the integration of Southern Cross Diagnostics.

• All geographic regions reported revenue growth, with the Americas exceeding 30% and Asia-Pacific around 22%.

• Continued progress on restructuring, expected to yield up to £4.0 million in annualized cost savings.

Financial highlights

• Group statutory revenue rose 18% year-over-year to about £11.6 million for H1 2026.

• Underlying revenue, excluding SCD, increased by 9%.

• Instrumentation segment achieved 30% year-over-year revenue growth; Clinical segment grew over 20%.

• SCD contributed approximately £1.8 million in revenue post-acquisition.

• Cash balance at 30 June 2026 was £8.9 million, down from £19.1 million at year-end 2025, reflecting acquisition outflows.

Outlook and guidance

• Restructuring program is expected to deliver significant cost savings and extend cash runway.

• IVDR accreditation for the new DPYD kit anticipated in the coming months.